اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,932
تعداد مقالات33,084
تعداد مشاهده مقاله43,729,806
تعداد دریافت فایل اصل مقاله20,242,371
Bargahi, Nasrin, Ghasemian, Abdolmajid, Hoseinpoor, Reyhaneh, Mahmoodi, Shirin. (1403). A concise review of major challenges in the vaccination, diagnosis and treatment of novel coronavirus disease 2019. سامانه مدیریت نشریات علمی, 79(6), 1155-1164. doi: 10.32592/ARI.2024.79.6.1155
Nasrin Bargahi; Abdolmajid Ghasemian; Reyhaneh Hoseinpoor; Shirin Mahmoodi. "A concise review of major challenges in the vaccination, diagnosis and treatment of novel coronavirus disease 2019". سامانه مدیریت نشریات علمی, 79, 6, 1403, 1155-1164. doi: 10.32592/ARI.2024.79.6.1155
Bargahi, Nasrin, Ghasemian, Abdolmajid, Hoseinpoor, Reyhaneh, Mahmoodi, Shirin. (1403). 'A concise review of major challenges in the vaccination, diagnosis and treatment of novel coronavirus disease 2019', سامانه مدیریت نشریات علمی, 79(6), pp. 1155-1164. doi: 10.32592/ARI.2024.79.6.1155
Bargahi, Nasrin, Ghasemian, Abdolmajid, Hoseinpoor, Reyhaneh, Mahmoodi, Shirin. A concise review of major challenges in the vaccination, diagnosis and treatment of novel coronavirus disease 2019. سامانه مدیریت نشریات علمی, 1403; 79(6): 1155-1164. doi: 10.32592/ARI.2024.79.6.1155

A concise review of major challenges in the vaccination, diagnosis and treatment of novel coronavirus disease 2019

Archives of Razi Institute
مقاله 5، دوره 79، شماره 6، بهمن و اسفند 2024، صفحه 1155-1164    اصل مقاله (315.24 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.32592/ARI.2024.79.6.1155
نویسندگان
Nasrin Bargahi1، 2؛ Abdolmajid Ghasemian3؛ Reyhaneh Hoseinpoor4؛ Shirin Mahmoodi* 5
1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;
2Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
4Department of Biotechnology, School of Advance Technologies in Medicine Shahid Beheshti University, Tehran, Iran
5Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
چکیده
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to 2019 coronavirus (COVID-19) pandemic worldwide. An efficient strategy to control the COVID-19 pandemic includes the rapid recognition of patients and vaccination using accurate and reliable methods. Various diagnostic methods such as CT scan, serology and molecular methods have been applied for the COVID-19 diagnosis. Moreover, various vaccines and antiviral drugs or immunotherapies have been utilized to combat the virus. This is particularly important for COVID-19 patients at high risk of serious consequences. Various challenges in the prognosis, diagnosis, vaccination and treatment of COVID-19 include variability in disease severity, emerging variants, individual factors and immune responses, co-infections and complications, limited long-term data, psychological and social factors, availability and accessibility, tests sensitivity and specificity, variability in symptoms, mild or asymptomatic cases, limited specific antiviral options, clinical heterogeneity, lack of universal treatment protocol, overwhelmed healthcare systems, management of severe cases, long-term effects and post-COVID syndrome, vaccine hesitancy, global cooperation and vaccine production capacity. This article describes the latest challenges and achievements in the prognosis, diagnosis, vaccination and therapy of COVID-19. The consult with reliable sources such as national health authorities and the World Health Organization (WHO) is crucial to obtain the latest information on COVID-19 vaccination, including eligibility, availability, and recommended protocols in any specific region. The treatment options and strategies continue to evolve. Healthcare professionals and researchers are working diligently to address therapy challenges and improve outcomes for individuals affected by COVID-19. Randomized clinical studies designed to identify the most appropriate and proven treatment are essential both to reduce the prevalence of COVID-19 and to prevent the prevalence of any pandemic in the future.
کلیدواژه‌ها
Coronavirus disease 2019؛ Prognosis؛ Vaccination؛ Diagnosis؛ Antiviral therapy
عنوان مقاله [English]
بررسی مختصر چالش‌های عمده در واکسیناسیون، تشخیص و درمان بیماری کروناویروس جدید 2019
مراجع
  1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
  2. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM. COVID-19: therapeutics and their toxicities. Journal of Medical Toxicology. 2020;16(3):284-94.
  3. Wagner CE, Saad-Roy CM, Grenfell BT. Modelling vaccination strategies for COVID-19. Nature Reviews Immunology. 2022;22(3):139-41.
  4. Meo S, Bukhari I, Akram J, Meo A, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021:1663-9.
  5. Ioannou GN, Locke ER, Green PK, Berry K. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the US Veterans Affairs healthcare system. EClinicalMedicine. 2022;45.
  6. Adjobimey T, Meyer J, Sollberg L, Bawolt M, Berens C, Kovačević P, et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines. Frontiers in Immunology. 2022;13:3094.
  7. Heidary M, Kaviar VH, Shirani M, Ghanavati R, Motahar M, Sholeh M, et al. A comprehensive review of the protein subunit vaccines against COVID-19. Frontiers in microbiology. 2022;13:927306.
  8. Yalçın TY, Topçu Dİ, Doğan Ö, Aydın S, Sarı N, Erol Ç, et al. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID‐19 infection: prospective observational study. Journal of medical virology. 2022;94(1):279-86.
  9. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368(6494):948-50.
  10. Araf Y, Akter F, Tang Yd, Fatemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS‐CoV‐2: genomics, transmissibility, and responses to current COVID‐19 vaccines. Journal of medical virology. 2022;94(5):1825-32.
  11. Guglielmi G. Rapid coronavirus tests: a guide for the perplexed. Nature. 2021;590(7845):202-5.
  12. Kralik P, Ricchi M. A basic guide to real time PCR in microbial diagnostics: definitions, parameters, and everything. Frontiers in microbiology. 2017;8:108.
  13. Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis—a review of current methods. Biosensors and Bioelectronics. 2021;172:112752.
  14. Merindol N, Pépin G, Marchand C, Rheault M, Peterson C, Poirier A, et al. SARS-CoV-2 detection by direct rRT-PCR without RNA extraction. Journal of Clinical Virology. 2020;128:104423.
  15. Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19. Medical hypotheses. 2020;141:109786.
  16. Park G-S, Ku K, Baek S-H, Kim S-J, Kim SI, Kim B-T, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Journal of Molecular Diagnostics. 2020;22(6):729-35.
  17. Yang W, Dang X, Wang Q, Xu M, Zhao Q, Zhou Y, et al. Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method. MedRxiv. 2020.
  18. Inaba M, Higashimoto Y, Toyama Y, Horiguchi T, Hibino M, Iwata M, et al. Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection. International Journal of Infectious Diseases. 2021;107:195-200.
  19. Jiang M, Pan W, Arasthfer A, Fang W, Ling L, Fang H, et al. Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19. Frontiers in cellular and infection microbiology. 2020;10:331.
  20. Yang W, Restrepo-Pérez L, Bengtson M, Heerema SJ, Birnie A, Van Der Torre J, et al. Detection of CRISPR-dCas9 on DNA with solid-state nanopores. Nano letters. 2018;18(10):6469-74.
  21. Lee H, Choi J, Jeong E, Baek S, Kim HC, Chae J-H, et al. dCas9-mediated nanoelectrokinetic direct detection of target gene for liquid biopsy. Nano letters. 2018;18(12):7642-50.
  22. Broughton JP, Deng X, Yu G, Fasching CL, Singh J, Streithorst J, et al. Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay. MedRxiv. 2020.
  23. Li S, Huang J, Ren L, Jiang W, Wang M, Zhuang L, et al. A one-step, one-pot CRISPR nucleic acid detection platform (CRISPR-top): application for the diagnosis of COVID-19. Talanta. 2021:122591.
  24. Han C, Li W, Li Q, Xing W, Luo H, Ji H, et al. CRISPR/Cas12a-Derived electrochemical aptasensor for ultrasensitive detection of COVID-19 nucleocapsid protein. Biosensors and Bioelectronics. 2021:113922.
  25. Lou J, Wang B, Li J, Ni P, Jin Y, Chen S, et al. The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases. Mol Biol Rep. 2022;49(12):11301-11.
  26. Sharma A, Balda S, Apreja M, Kataria K, Capalash N, Sharma P. COVID-19 diagnosis: current and future techniques. International Journal of Biological Macromolecules. 2021;193:1835-44.
  27. Zhou Y, Wu Y, Ding L, Huang X, Xiong Y. Point-of-care COVID-19 diagnostics powered by lateral flow assay. TrAC Trends in Analytical Chemistry. 2021;145:116452.
  28. Mattioli IA, Castro KR, Macedo LJ, Sedenho GC, Oliveira MN, Todeschini I, et al. Graphene-based hybrid electrical-electrochemical point-of-care device for serologic COVID-19 diagnosis. Biosensors and Bioelectronics. 2022;199:113866.
  29. Beduk T, Beduk D, de Oliveira Filho JI, Zihnioglu F, Cicek C, Sertoz R, et al. Rapid Point-of-Care COVID-19 Diagnosis with a Gold-Nanoarchitecture-Assisted Laser-Scribed Graphene Biosensor. Analytical chemistry. 2021.
  30. Yu S, Nimse SB, Kim J, Song K-S, Kim T. Development of a lateral flow strip membrane assay for rapid and sensitive detection of the SARS-CoV-2. Analytical chemistry. 2020;92(20):14139-44.
  31. Xia S, Chen X. Single-copy sensitive, field-deployable, and simultaneous dual-gene detection of SARS-CoV-2 RNA via modified RT–RPA. Cell discovery. 2020;6(1):1-4.
  32. Wensel CR, Pluznick JL, Salzberg SL, Sears CL. Next-generation sequencing: insights to advance clinical investigations of the microbiome. J Clin Invest. 2022;132(7).
  33. Dotolo S, Esposito Abate R, Roma C, Guido D, Preziosi A, Tropea B, et al. Bioinformatics: from NGS data to biological complexity in variant detection and oncological clinical practice. Biomedicines. 2022;10(9):2074.
  34. D’Alessandra Y, Valerio V, Moschetta D, Massaiu I, Bozzi M, Conte M, et al. Extraction-Free Absolute Quantification of Circulating miRNAs by Chip-Based Digital PCR. Biomedicines. 2022;10(6):1354.
  35. Lewandowski K, Xu Y, Pullan ST, Lumley SF, Foster D, Sanderson N, et al. Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples. J Clin Microbiol. 2019;58(1).
  36. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 2020;382(24):2327-36.
  37. Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the treatment of covid-19-preliminary report. N Engl J Med. 2020;383(10):992.
  38. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017;93(7):449-63.
  39. Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clinical Pharmacology & Therapeutics. 2020;108(2):242-7.
  40. Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors. Journal of theoretical biology. 2008;254(4):861-7.
  41. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option. Journal of medical virology. 2020;92(6):556-63.
  42. Abd‐Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical Study Evaluating the Efficacy of Ivermectin in COVID‐19 Treatment: A Randomized Controlled Study. Journal of medical virology. 2021.
  43. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020.
  44. In Ah C, Sang Jin L, Won P, Sung Hwan P, Seung-cheol S, Han Joo B, et al. Effects of tocilizumab therapy on serum interleukin-33 and interleukin-6 levels in patients with rheumatoid arthritis. Archives of rheumatology. 2018;33(4):389.
  45. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial agents and chemotherapy. 1994;38(8):1695-702.
  46. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. The Journal of clinical investigation. 2020;130(6):2757-65.
  47. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clinical infectious diseases. 2020;71(16):2027-34.
  48. Shende P, Bhandarkar S, Prabhakar B. Heat shock proteins and their protective roles in stem cell biology. Stem Cell Reviews and Reports. 2019;15(5):637-51.
  49. Golchin A. Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility. Stem cell reviews and reports. 2021;17(1):56-62.
  50. Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Frontiers of medicine. 2020;14(5):664-73.
  51. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020;579(7798):270-3.
  52. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin OG, Pickles A, et al. Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust. European journal of heart failure. 2020;22(6):967-74.
  53. Fahrni ML, Ismail IA, Refi DM, Almeman A, Yaakob NC, Saman KM, et al. Management of COVID-19 vaccines cold chain logistics: a scoping review. J Pharm Policy Pract. 2022;15(1):16.
  54. Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12):e0008961.
  55. Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825-32.
  56. Mukherjee S, Kalra K, Phelan AL. Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries. PLOS Glob Public Health. 2023;3(6):e0002098.
  57. Vakil MK, Mansoori Y, Al-Awsi GRL, Hosseinipour A, Ahsant S, Ahmadi S, et al. Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll-like receptors dictates pathophysiology of COVID-19 disease. J Med Virol. 2022;94(9):4088-96.
  58. Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9(6).
  59. Samantaray NN, Kar N, Mishra SR. A follow-up study on treatment effects of cognitive-behavioral therapy on social anxiety disorder: Impact of COVID-19 fear during post-lockdown period. Psychiatry Res. 2022;310:114439.
  60. Böger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control. 2021;49(1):21-9.
  61. Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, et al. COVID-19 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022;29(34):51384-97.
  62. Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142:112015.
  63. Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2021;10(2).
  64. Hosseinzadeh S, Ketabi S, Atighehchian A, Nazari R. Hospital bed capacity management during the COVID-19 outbreak using system dynamics: A case study in Amol public hospitals, Iran. International Journal of Healthcare Management. 2022:1-13.
آمار
تعداد مشاهده مقاله: 163
تعداد دریافت فایل اصل مقاله: 316


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب